*School of Biomedical Sciences; and
†Institute for Molecular Biosciences, The University of Queensland, Brisbane, Queensland, Australia
‡Department of Biological and Physical Sciences, University of Southern Queensland, Toowoomba, Queensland, Australia.
Reprints: Lindsay Brown, PhD, Department of Biological and Physical Sciences, University of Southern Queensland, Toowoomba, Queensland 4350, Australia (e-mail: [email protected]).
Supported in part by the National Health and Medical Research Council of Australia and Dr Red Nutraceuticals, Mt Nebo, Queensland, Australia; the ANZ Trustees Medical Research in Queensland Program (A.I.); the Australian Research Council for a Federation Fellowship (to D.P.F.).
D. P. Fairlie was the Scientific Director, CSO, and one of the founders of Promics Pty, Ltd, at the time these studies were initiated.
D. P. Fairlie, S. M. Taylor, and L. Brown are inventors on several patents associated with PMX53 and filed by The University of Queensland.
The authors report no conflicts of interest.
Received April 18, 2011
Accepted June 21, 2011
